GlassScriptPhysician profile
Loralyn Wafful
NPI 1316497985
$3,322.19
in general payments reported to CMS, 2019-2025
20 companies · $1,199 in 2025
The $1,199 reported for 2025 was more than what 83% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $198 · 2024: $1,925 · 2025: $1,199.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,039 · Education: $283.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,039.26 |
| Education | $282.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $644.70 | 2023-2025 | |
| Janssen Biotech, INC. | $375.09 | 2023-2025 | Tremfya |
| Galderma Laboratories, L.P. | $359.52 | 2024-2025 | Aklief, Nemluvio |
| E.R. Squibb & Sons, L.L.C. | $274.86 | 2023-2025 | Sotyktu |
| Pfizer INC. | $256.69 | 2025 | |
| Dermavant Sciences, INC. | $208.01 | 2024 | Vtama |
| Lilly USA, LLC | $178.36 | 2023-2024 | Olumiant, Taltz, Ebglyss |
| Arcutis Biotherapeutics, INC. | $175.64 | 2024-2025 | Zoryve |
| Genzyme Corporation | $159.68 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $146.37 | 2023-2024 | Dupixent |
| Amgen INC. | $108.79 | 2024 | Otezla |
| Incyte Corporation | $103.73 | 2025 | Opzelura |
| Ucb, INC. | $90.37 | 2024-2025 | Bimzelx |
| Novartis Pharmaceuticals Corporation | $63.34 | 2025 | |
| Sun Pharmaceutical Industries INC. | $41.55 | 2024 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biofrontera INC. | $37.18 | 2024-2025 | Xepi, Bf-Rhodoled, Ameluz |
| Fresenius Kabi USA, LLC | $29.40 | 2024 | Idacio |
| Cipher Pharmaceuticals US LLC | $27.61 | 2025 | Spinosad, Natroba |
| Verrica Pharmaceuticals INC. | $22.79 | 2023 | Ycanth |
| Krystal Biotech INC | $18.51 | 2024 | Vyjuvek |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Loralyn Wafful listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.